Bosutinib (SKI-606) - Moligand™, 10mM in DMSO , Tyrosine-protein kinase Lyn inhibitor, CAS No.380843-75-4, Tyrosine-protein kinase Lyn inhibitor

CAS: 380843-75-4 Cat. No.: B407917 Formula: C₂₆H₂₉Cl₂N₅O₃ Peso molecolare: 530.45 Numero EC: 700-455-1

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

Information

Bosutinib (SKI-606) is a novel, dualSrc/Ablinhibitor withIC50of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity ofPI3K/AKT/mTOR,MAPK/ERKandJAK/STAT3signaling pathways by blocking the phosphorylation lev
In vitro

Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin.

In vivo

Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts.
Cell Data

cell lines：Gli-Luc/MEF cells

Concentrations：Dissolved in DMSO, final concentrations ~1 μM

Incubation Time：72 hours

Powder Purity:≥98%

Specifications

Sinonimi

4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Specifiche e purezza

Moligand™, 10mM in DMSO

Meccanismi biochimici e fisiologici

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphoryl

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Grado

Moligand™

Tipo di azione

INHIBITOR

Meccanismo d'azione

Tyrosine-protein kinase Lyn inhibitor

Proprietà del prodotto

ALogP

5.4

Nomi e identificatori

Isomeri SMILES

CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC

WGK Germania

3

Peso molecolare

530.45

Reaxy-Rn

9100307

Reaxys-RN_link_address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9100307&ln=

Obiettivi associati (umani)

CTH Tchem Cystathionine gamma-lyase (0 Activities)

Discover Target: CTH

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

EPHA2 Tclin Ephrin type-A receptor 2 (1 Activities)

Discover Target: EPHA2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

EPHA4 Tchem Ephrin type-A receptor 4 (1 Activities)

Discover Target: EPHA4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

EPHA8 Tchem Ephrin type-A receptor 8 (1 Activities)

Discover Target: EPHA8

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

EPHB4 Tchem Ephrin type-B receptor 4 (2 Activities)

Discover Target: EPHB4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ERBB4 Tclin Receptor tyrosine-protein kinase erbB-4 (1 Activities)

Discover Target: ERBB4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

EPHA5 Tchem Ephrin type-A receptor 5 (1 Activities)

Discover Target: EPHA5

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ERBB3 Tclin Receptor tyrosine-protein kinase erbB-3 (1 Activities)

Discover Target: ERBB3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor (4 Activities)

Discover Target: EGFR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

EPHA3 Tchem Ephrin type-A receptor 3 (1 Activities)

Discover Target: EPHA3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SRC Tclin Proto-oncogene tyrosine-protein kinase Src (28 Activities)

Discover Target: SRC

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

STK10 Tchem Serine/threonine-protein kinase 10 (2 Activities)

Discover Target: STK10

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

STK24 Tchem Serine/threonine-protein kinase 24 (3 Activities)

Discover Target: STK24

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

STK35 Tchem Serine/threonine-protein kinase 35 (1 Activities)

Discover Target: STK35

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

STK4 Tchem Serine/threonine-protein kinase 4 (1 Activities)

Discover Target: STK4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

TXK Tchem Tyrosine-protein kinase TXK (1 Activities)

Discover Target: TXK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

YES1 Tclin Tyrosine-protein kinase Yes (2 Activities)

Discover Target: YES1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

FRK Tchem Tyrosine-protein kinase FRK (4 Activities)

Discover Target: FRK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

FYN Tclin Tyrosine-protein kinase Fyn (3 Activities)

Discover Target: FYN

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

GAK Tchem Cyclin-G-associated kinase (3 Activities)

Discover Target: GAK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

FGR Tchem Tyrosine-protein kinase Fgr (2 Activities)

Discover Target: FGR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CAMK1D Tchem Calcium/calmodulin-dependent protein kinase type 1D (1 Activities)

Discover Target: CAMK1D

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SIK1 Tchem Serine/threonine-protein kinase SIK1 (1 Activities)

Discover Target: SIK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SIK2 Tchem Serine/threonine-protein kinase SIK2 (2 Activities)

Discover Target: SIK2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

TNIK Tchem TRAF2 and NCK-interacting protein kinase (1 Activities)

Discover Target: TNIK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SIK3 Tchem Serine/threonine-protein kinase SIK3 (1 Activities)

Discover Target: SIK3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SLK Tchem STE20-like serine/threonine-protein kinase (1 Activities)

Discover Target: SLK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PKMYT1 Tchem Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (2 Activities)

Discover Target: PKMYT1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MINK1 Tchem Misshapen-like kinase 1 (2 Activities)

Discover Target: MINK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MAP2K2 Tclin Dual specificity mitogen-activated protein kinase kinase 2 (1 Activities)

Discover Target: MAP2K2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MAP4K2 Tchem Mitogen-activated protein kinase kinase kinase kinase 2 (2 Activities)

Discover Target: MAP4K2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

LCK Tclin Tyrosine-protein kinase Lck (2 Activities)

Discover Target: LCK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MAP4K3 Tchem Mitogen-activated protein kinase kinase kinase kinase 3 (2 Activities)

Discover Target: MAP4K3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MAP4K4 Tchem Mitogen-activated protein kinase kinase kinase kinase 4 (1 Activities)

Discover Target: MAP4K4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MAP4K5 Tchem Mitogen-activated protein kinase kinase kinase kinase 5 (4 Activities)

Discover Target: MAP4K5

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

LYN Tclin Tyrosine-protein kinase Lyn (4 Activities)

Discover Target: LYN

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BTK Tclin Tyrosine-protein kinase BTK (3 Activities)

Discover Target: BTK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BMX Tchem Cytoplasmic tyrosine-protein kinase BMX (2 Activities)

Discover Target: BMX

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BCR Tclin Breakpoint cluster region protein (1 Activities)

Discover Target: BCR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BLK Tchem Tyrosine-protein kinase Blk (1 Activities)

Discover Target: BLK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

TNK2 Tclin Activated CDC42 kinase 1 (4 Activities)

Discover Target: TNK2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ABL2 Tchem Tyrosine-protein kinase ABL2 (3 Activities)

Discover Target: ABL2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL1 (23 Activities)

Discover Target: ABL1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

HCK Tclin Tyrosine-protein kinase HCK (3 Activities)

Discover Target: HCK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

NTRK2 Tclin BDNF/NT-3 growth factors receptor (1 Activities)

Discover Target: NTRK2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

NTRK1 Tclin High affinity nerve growth factor receptor (1 Activities)

Discover Target: NTRK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CAMK2G Tchem Calcium/calmodulin-dependent protein kinase type II subunit gamma (1 Activities)

Discover Target: CAMK2G

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MAP2K1 Tclin Dual specificity mitogen-activated protein kinase kinase 1 (2 Activities)

Discover Target: MAP2K1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MAP2K5 Tchem Dual specificity mitogen-activated protein kinase kinase 5 (1 Activities)

Discover Target: MAP2K5

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Proprietà chimiche e fisiche

• Solubilità: Solubility (25°C) In vitro DMSO: 47 mg/mL (199.05 mM); Water: 47 mg/mL (199.05 mM); Ethanol: 10 mg/mL (42.35 mM)

Application Protocols

No item-specific, validated application protocols are provided for this SKU.

General literature guidance (non-validated; for planning only):

• Stock preparation: Dissolve in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM), vortex and, if necessary, sonicate briefly. Filter sterilize if required for cell work.
• Biochemical kinase assays: Titrate over several log units to establish IC50 under your assay conditions; include matched DMSO controls.
• Cell-based assays: Start with sub-μM to low-μM ranges, adjusting based on target expression and exposure time; monitor for solvent effects and cytotoxicity.

For step-by-step, validated procedures, consult peer-reviewed literature for your specific target system and use the product’s SDS/CoA for material handling information.

Biological Roles

Bosutinib is widely used as a chemical biology probe to interrogate kinase-mediated signaling.

• Mechanism and target class (literature/general)

  • ATP-competitive inhibitor with primary activity against ABL1/BCR-ABL and Src-family kinases; also exhibits activity on a subset of additional kinases at higher concentrations depending on assay conditions.
  • Engages the kinase hinge region via heteroaromatic interactions; substituents orient into hydrophobic pockets, supporting type I binding.

• Research utilities

  • Dissection of Src/ABL-dependent pathways in cell lines and biochemical systems, enabling modulation of phosphorylation events and phenotypic outputs.
  • Benchmarking selectivity in kinome profiling to validate screening platforms and inform SAR decision-making.
  • Use as a control in degradation (PROTAC) studies where a bosutinib-derived warhead is employed, separating warhead-driven vs degradation-driven effects.

• Off-target considerations (literature/general)

  • Like many kinase inhibitors, target engagement can broaden with increasing concentration and time; careful titration and orthogonal readouts (e.g., phospho-substrate panels) are recommended.

• ADME/biophysical context (general)

  • Moderately lipophilic with basic centers; cellular potency can be influenced by protein binding, lysosomal sequestration, and transporter interactions—factors to consider when translating biochemical potency to cellular effects.

No medical or clinical claims are made. This product is for laboratory research use only.

Buffer Applications

This product is not a buffering agent and is not typically used to prepare buffer systems. For experimental use, bosutinib is usually delivered in small volumes of organic cosolvent (e.g., DMSO) into pre-existing biological buffers.

• Practical note: Validate buffer compatibility (ionic strength, pH 6.5–7.5 typical for kinase assays) and keep organic solvent percentages as low as your assay permits to maintain protein stability and signal quality.

Green Alternatives

As a finished bioactive tool compound, bosutinib itself does not have a “greener substitute” in the sense of a solvent or commodity reagent. However, greener choices can be made around its handling and formulation.

• Greener solvent/formulation considerations (general)

  • Prefer aqueous buffers with minimal DMSO carryover (≤0.1% v/v) when assay sensitivity allows.
  • Where high-organic stocks are required, DMSO is generally preferable to DMF or NMP from a worker-safety perspective and regulatory profile.
  • Consider hydroxypropyl-β-cyclodextrin (HPβCD) or PEG-based cosolvents to reduce organic solvent percentages in dose solutions.

• Process and waste minimization

  • Use small-volume, high-concentration stocks to minimize solvent use.
  • Adopt microplate-based assays and acoustic dispensing to reduce plastic and solvent waste.
  • Consolidate analytical runs (LC–MS) to lower sample throughput and solvent consumption.

• Example comparison (general intent; not product specs)

  • DMSO vs DMF/NMP: DMSO typically offers lower chronic toxicity concerns and better biodegradability profile; DMF/NMP may pose reproductive toxicity hazards and should be avoided when possible.

Note: These recommendations concern the surrounding workflow. The molecular identity of bosutinib is intrinsic to its research function; substituting with another chemical will change target engagement properties.

Pharmaceutical Uses

This listing is supplied for research use only and is not intended for human or veterinary use or for use as an API.

• Research/formulation roles (general)

  • Reference material in analytical method development (e.g., LC–MS/MS) and system suitability testing.
  • Positive-control inhibitor in target engagement and kinase activity assays during discovery research.
  • Potential internal standard/benchmark in stability-indicating studies for heteroaromatic kinase inhibitors.

• Regulatory/compendial status: Not specified for this item; refer to CoA/Spec Sheet. No claims are made regarding pharmacopeial compliance.

• Excipient status: Not applicable.

Any use in GMP or clinical settings would require separate, appropriately qualified material; this Moligand™ product is not offered for such applications.

Physical Properties

Item-specific physicochemical data were not provided with this listing. Where helpful, commonly cited literature values are noted for context and should not be construed as specifications for SKU B407917.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: ~530.45 g/mol (literature, free base). Note: different salt/hydrate forms have different MW.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet. (Literature values vary by form/polymorph.)
• Boiling point: Not applicable (decomposes before boiling; literature generality for complex kinase inhibitors).
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• pKa(s): Reported basic pKa values associated with tertiary amine functionality (literature, qualitative); exact values vary by method and form and are not specified for this item.
• LogP/logD: Reported as moderately lipophilic in the kinase inhibitor range (literature, qualitative); numerical values are not specified for this item.
• Solubility (qualitative, literature):
  • Soluble in DMSO and DMF; often prepared as concentrated DMSO stock solutions for screening.
  • Low aqueous solubility at neutral pH; aqueous uptake can be improved using cosolvent, cyclodextrin, or pH adjustment strategies.
• UV/Vis: Kinase hinge-binding heteroaromatics typically show UV absorbance in the 200–350 nm range (literature, qualitative). No item-specific UV cutoff provided.

For exact, reportable physical property values applicable to this SKU, consult the item’s CoA/Spec Sheet.

Quality and Grades

• Grade/Purity: Moligand™

  • Moligand™ indicates suitability for use as a research ligand/tool compound in screening libraries and assay development. Emphasis is on identity and practical purity for discovery workflows rather than chromatographic solvent grades or biopharma GMP standards.
  • Typical expectations (general, for library-grade small molecules): verified identity (e.g., NMR/LC–MS), assay-ready purity suitable for screening, and stability controls for shipment and storage. Item-specific acceptance criteria are defined on the CoA.

• What this means for your experiments

  • Appropriate for biochemical and cell-based assays, target profiling, and SAR benchmarking where bosutinib serves as a positive control/standard.
  • If you require quantified levels of residual solvents, water content, or metal contaminants: Not specified for this item; refer to CoA/Spec Sheet or request additional QC documentation.

• Stabilizers/additives

  • None specified for this item. If present, stabilizers would be disclosed on the CoA; absence or presence can affect solubility and assay performance.

• Comparison to other common grades (general explanation)

  • Research/tool compound (this item): optimized for screening fidelity and identity confirmation.
  • Analytical reference standard: tightly defined purity/assay with certified values for quantitative methods.
  • GMP/clinical grade: manufactured under cGMP with full regulatory documentation (not applicable here; this product is for research use only).

Reaction and Applications

This product is supplied as a finished research ligand/tool compound rather than a synthetic reagent. Its primary applications are in chemical biology and screening.

• Research applications (literature/general)

  • Positive control/benchmark inhibitor for ABL1/BCR-ABL and Src-family kinase assays (biochemical and cellular) to validate assay windows and signal-to-background.
  • Target profiling across kinome panels to calibrate selectivity metrics, help train predictive models, and anchor SAR analyses.
  • Chemical probe in pathway interrogation studies (e.g., modulation of Src/ABL signaling) to dissect phosphorylation cascades and feedback regulation.
  • Reference compound in method development for LC–MS/MS bioanalytical assays and in stability testing workflows.

• Practical usage notes

  • Prepare concentrated DMSO stocks and store in aliquots to avoid freeze–thaw cycles; verify concentration by UV if appropriate (determine ε experimentally under your conditions).
  • Include solvent controls at matching DMSO percentages to isolate compound effects from carrier effects.
  • For cellular assays, confirm uptake and exposure time dependence; many kinase inhibitors show time-dependent potency shifts due to intracellular accumulation.

• Not typically used in synthetic transformations of other substrates. If derivatization for probe development (e.g., linkers, tags, PROTAC-like constructs) is planned, medicinal chemistry optimization and full analytical re-characterization are required.

Reaction Conditions

Not typically applicable. Bosutinib is provided as a finished small-molecule probe, not as a reagent or catalyst in organic synthesis.

• For users pursuing derivatization (general literature guidance):
  • Solvents: anhydrous polar aprotics (DMSO, DMF) are often employed for heteroaromatic coupling or substitution steps on related scaffolds.
  • Conditions: mild bases and carefully controlled temperatures are preferred to preserve sensitive heteroaromatic motifs; avoid strong acids/oxidants that can degrade the scaffold.
  • Purification: reverse-phase preparative HPLC is commonly required due to polarity and close-running impurities.

These notes are general and not specific to this SKU; no standardized reaction conditions apply to the as-supplied compound.

Safety and Handling

Safety information specific to this item was not provided. Treat bosutinib as a bioactive small molecule with potential systemic activity. Always consult the product SDS for authoritative guidance.

• GHS classification, signal word, pictograms, H-statements: Not specified for this item; refer to SDS.
• General hazards (literature/general): Bioactive kinase inhibitors may present acute toxicity if ingested, inhaled, or absorbed through skin; avoid exposure and environmental release.
• Personal protective equipment (PPE):
  • Use lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile).
  • Handle powders and stock solutions in a certified chemical fume hood or ventilated enclosure to minimize inhalation exposure.
• Handling practices:
  • Minimize aerosol/particle generation when weighing.
  • Use dedicated tools and wipe down surfaces after use to avoid cross-contamination of screening collections.
• Incompatibilities: Avoid strong oxidizers and strong acids/bases that may degrade heteroaromatic systems (general chemical guidance).
• First aid overview (general):
  • Inhalation: Move to fresh air; seek medical attention if symptoms occur.
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention if irritation persists.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
• Spill response: Avoid dust formation; absorb solutions with inert material; collect in labeled hazardous-waste container.

Always defer to and follow the SDS and institutional EHS policies for this specific product.

Solvent Selection

Bosutinib is a moderately lipophilic, heteroatom-rich kinase inhibitor. Solvent choice primarily impacts dissolution for stock preparation and compatibility with biological assays.

• Primary solvents (literature/practice):

  • DMSO: Preferred for high-concentration stocks (e.g., 10–50 mM typical in screening practice). Offers broad compatibility with biochemical and cell-based assays at low final percentages.
  • DMF or NMP: Alternative polar aprotic solvents when DMSO is contraindicated; verify assay tolerance.
  • Ethanol: Can be used at lower concentrations; often requires cosolvent strategies for higher stocks.

• Aqueous handling (general):

  • Low intrinsic water solubility at neutral pH; use DMSO cosolvent (e.g., final 0.1–1% v/v in assay) or solubilizing excipients (cyclodextrins, surfactants) as assay permits.
  • pH adjustment may modestly enhance solubility due to basic amine(s), but avoid conditions that compromise target biology.

• Dielectric/polarity context (general):

  • Bosutinib dissolves well in high-dielectric, hydrogen-bond–accepting media (DMSO, DMF) and poorly in nonpolar solvents.

• Practical selection tips

  • Start with DMSO for reproducible stocks; filter sterilize through low-protein-binding membranes if sterility is required.
  • Validate solvent tolerance in your specific assay readout (fluorescence quenching/inner filter effects can occur with aromatic inhibitors).

• Quick comparison (general)

  • DMSO: best solubilizer; high assay compatibility at ≤0.5% v/v.
  • DMF/NMP: strong solubilizers; assess cytotoxicity/background.
  • Aqueous buffers: require cosolvent or formulation aids for clear solutions.

Storage and Reconstitution

• Storage conditions (item-specific): Store at -80°C. Shipment on dry ice packs + cold packs as provided.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

• Stability: No explicit shelf-life or stability data are provided for this SKU; consult CoA for retest/expiry information. Minimize exposure to light, moisture, and repeated freeze–thaw.

• Reconstitution

  • Item-specific instructions: Not specified for this item; refer to CoA/Spec Sheet.
  • General guidance (literature/practice): Prepare concentrated stock solutions in anhydrous DMSO. Aliquot into small volumes in chemically resistant, low-bind tubes; purge headspace with inert gas if long-term storage is anticipated. Store aliquots at ≤ -20°C to -80°C. Avoid multiple freeze–thaw cycles; thaw at room temperature, vortex to homogeneity, and immediately return unused aliquots to cold storage.
  • Aqueous working solutions: Prepare fresh on the day of use by diluting the DMSO stock into assay buffer with vigorous mixing. Maintain consistent final DMSO percentage across controls and treatments.

• Adsorption/containers (general): Use glass or high-quality polypropylene; pre-rinse pipette tips with solution to minimize adsorption losses of hydrophobic inhibitors.

Always consult the product’s CoA and SDS for authoritative, item-specific instructions.

Structure and Identity

Bosutinib (SKI-606) is a research-grade, ATP-competitive small-molecule kinase inhibitor commonly used as a reference tool compound in kinase panels and chemical biology.

• Product identifiers

  • SKU: B407917
  • Product Name: Bosutinib (SKI-606)
  • CAS: 380843-75-4
  • PubChem CID: 5328940
  • Category: Small molecules and compound libraries (筛选/化合物库)

• Structure identifiers

  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.

• Composition

  • Molecular formula: C26H29Cl2N5O3 (literature, free base)
  • Molecular weight: ~530.45 g/mol (literature, free base)

• Structural features (literature description)

  • Contains a dihalo-heteroaromatic kinase-binding hinge motif (dichloro–azaheteroarene) consistent with type I ATP-site engagement.
  • Presents a tertiary amine-containing, polar tail and ether linkages that modulate solubility and kinase pocket fit.
  • Multiple hydrogen-bond acceptors (ring nitrogens, amide/carboxamide-like carbonyl) and limited donors; overall moderately lipophilic with polar functionality enabling kinase hinge interactions.
  • 2D description: a substituted heteroaromatic core bearing two chlorines is linked via an anilide/aryloxy spacer to a tertiary amine side chain; additional heteroatoms (O, N) populate the periphery for solubility and binding orientation.

Notes: Exact stereochemistry is not applicable (bosutinib is achiral as typically supplied). All identifiers not explicitly provided here should be verified against the item-specific CoA.

Synthetic Utility

Bosutinib is supplied as a finished tool compound and is not generally employed as a synthetic reagent. Nevertheless, in medicinal chemistry contexts it can serve as a scaffold for probe development.

• As a derivatization starting point (literature/general)

  • Researchers have appended linkers or reporter groups to bosutinib-like warheads to generate affinity probes or degrader molecules for kinase-focused studies.
  • Such work requires identification of vector positions that tolerate modification without ablating target engagement; this is highly system- and design-dependent.

• Functional group context (general)

  • Multiple heteroatoms (N, O) in the core and side chains provide sites potentially amenable to protection/modification, but uncontrolled changes often disrupt potency/selectivity.
  • The molecule lacks simple, free carboxylic acid or primary amine “handles” in many forms; semi-synthesis often starts from advanced intermediates rather than the final drug-like molecule.

• Recommendation

  • If synthetic modification is desired, consider starting from published intermediates or leveraging custom synthesis services; fully re-characterize any derivative (NMR, HRMS, HPLC/UPLC purity, and if relevant, chiral analysis).

Target Specificity

Not specified for this item; refer to CoA/Spec Sheet.

General literature note: Bosutinib is widely used as a research inhibitor of ABL1/BCR-ABL and Src-family kinases. Exact potency and selectivity depend on assay format, protein construct, and conditions and are not specified for this SKU.